Skip to content

The study of median effective volume of 0.375% ropivacaine for inferior articular process thoracic paravertebral nerve block

The study of median effective volume of 0.375% ropivacaine for inferior articular process thoracic paravertebral nerve block

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069383
Enrollment
Unknown
Registered
2023-03-15
Start date
2022-11-19
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Experimental group:inferior articular process thoracic paravertebral nerve block

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. ASA Class I-II; 2. Aged 18-64 years; 3. BMI 18-35 kg/m2; 4. Patients to undergo thoracoscopic lobectomy; 5. Patients are willing to participate in this study and cooperate with the follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cardiopulmonary disease; 2. Those with coagulation disorders; 3. Skin infection at the puncture site; 4. Patients who are unable to communicate, such as speech impairment or severe hearing impairment; 5. Patients with preoperative psychosis, history of severe dementia, schizophrenia; 6. Patients with a history of previous thoracic or thoracic spine surgery or thoracic spine deformity.

Design outcomes

Primary

MeasureTime frame
Segment of decreased or absent pain sensation ;Total number of PCIA compressions ;Visual Analogue Score at rest and activity ;

Secondary

MeasureTime frame
Incidence of arrhythmia after block;Incidence of hypotension after block;Incidence of epidural block;Incidence of nausea after block;Incidence of vomiting after block;Incidence of pruritus after block;

Countries

China

Contacts

Public ContactZhihang Tang

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

267033734@qq.com+8618078840754

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026